Table 2.
Direction of change in PD-L1 tumor proportion score following NACT in relation to clinicopathologic characteristics
| Clinicopathologic variable | Unchanged or downward (n=52) | Upward (n=34) | p-value |
|---|---|---|---|
| Age at surgery (yr) | 62.5 (37-76) | 61 (38-79) | 0.572 |
| Sex | |||
| Male | 46 (88.5) | 24 (70.6) | 0.049 |
| Female | 6 (11.5) | 10 (29.4) | |
| Smoking history | |||
| Never-smoker | 5 (9.6) | 6 (17.6) | 0.331 |
| Current or former smoker | 47 (90.4) | 28 (82.4) | |
| Histological diagnosis | |||
| Adenocarcinoma | 17 (32.7) | 10 (29.4) | 0.476 |
| Squamous cell carcinoma | 30 (57.7) | 23 (67.6) | |
| Others | 5 (9.6) | 1 (2.9) | |
| Pretreatment clinical stage | |||
| I-II | 11 (21.2) | 11 (32.4) | 0.314 |
| III-IV | 41 (78.8) | 23 (67.6) | |
| Pathologic T category | |||
| ypT1-2 | 36 (69.2) | 21 (61.8) | 0.493 |
| ypT3-4 | 16 (30.8) | 13 (38.2) | |
| Pathologic N category | |||
| ypN0 | 14 (26.9) | 10 (29.4) | 0.811 |
| ypN1-3 | 38 (73.1) | 24 (70.6) | |
| NACT regimen | |||
| Gemcitabine plus platinum | 36 (69.2) | 22 (64.7) | 0.644 |
| Taxane plus platinum | 13 (25.0) | 11 (32.4) | |
| Others | 3 (5.8) | 1 (2.9) | |
| Best objective response to NACT | |||
| PR | 33 (63.5) | 12 (35.3) | 0.015 |
| SD | 19 (36.5) | 22 (64.7) |
Values are presented as median (range) or number (%). PD-L1, programmed death ligand 1; NACT, neoadjuvant chemotherapy; PR, partial response; SD, stable disease.